Jorge Nieva, MD

Jorge Nieva, MD, discusses how long-term responses in ROS1+ non–small cell lung cancer affect imaging frequency, MRD testing, and treatment intensification.

Jorge Nieva, MD, reviews long-term taletrectinib data in ROS1+ non–small cell lung cancer, including about 90% response rates across fusion partners and manageable safety.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

A 940-patient real-world study confirms alectinib outperforms crizotinib in ALK-positive NSCLC, mirroring results from the landmark ALEX trial.

Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.